Oral corticosteroids did not reduce symptom severity or duration in patients with lower respiratory tract infections without asthma.
Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.
Canakinumab vs placebo showed promising results in preventing recurrent cardiovascular events and incidences of lung cancer.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
Asking patients to stop smoking before undergoing cosmetic surgery can promote long-term smoking cessation with 40.5% of participants in a recent study no longer smoking on a daily basis.
People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.
Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.
The correlation between patient race and ethnicity and administration of antibiotic treatment for viral acute respiratory tract infections was examined.
Adults with asthma benefit from tailoring interventions based on sputum eosinophils vs clinical symptoms.
Researchers analyzed over 2.1 million patient-years' worth of data to determine the impact of short-acting beta agonist use in asthma.
Participants received 70 mg of tezepelumab every 4 weeks throughout the study.
A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.
FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.
Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.
Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.
The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.
Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.
The pathogeneses of steroid insensitivity in severe, steroid-resistant asthma may unlock new potential treatments.
Fluticasone furoate and vilanterol combination therapy reduced both daytime and nighttime symptoms in patients with persistent uncontrolled asthma.
Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.